Telix Pharmaceuticals Limited (TLX) Stock Forecast
TLX analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 5 analysts
- Price target
- $20.57 average of analyst targets
- Upside to target
- +92.4% from the latest close
- Next earnings
- —
- 52-week range
- $6.41 – $12.83
TLX analyst ratings
5 analystsNumber of analysts at each rating.
TLX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
TLX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.07 | $0.07 | $0.07 | — | — | 1 |
| Current fiscal year (2026) | $0.15 | $0.03 | $0.39 | −$0.03 | +599.0% | 5 |
| Next fiscal year (2027) | −$0.04 | −$0.04 | −$0.03 | $0.15 | −125.8% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
TLX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $329.4M | $276.2M | $364.0M | +3.6% | 3 |
| Current fiscal year (2026) | $1.39B | $1.36B | $1.44B | +16.1% | 16 |
| Next fiscal year (2027) | $1.58B | $1.49B | $1.76B | +13.8% | 9 |
TLX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
TLX revenue: reported and forecast
TLX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.04 | $0.01 | $0.00 | $0.00 | $0.07 | +62.8% | 1 up · 0 down |
| Current fiscal year (2026) | $0.13 | $0.09 | $0.15 | $0.15 | $0.15 | +17.5% | 3 up · 1 down |
| Next fiscal year (2027) | $0.33 | $0.26 | $0.20 | −$0.04 | −$0.04 | −111.8% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
TLX earnings surprises
Reported EPS vs the consensus estimate for the last 6 quarters; TLX beat in 4 of 6.
What analysts expect from TLX
5 analysts cover Telix Pharmaceuticals; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $20.57, 92.4% above the latest close of $10.69. Analysts expect earnings of $0.15 per share for 2026, +599.0% from a year earlier. For 2027 the average estimate is −$0.04 per share on revenue of $1.6 billion. Telix Pharmaceuticals beat the EPS estimate in 4 of the last 6 quarters.
Related: TLX income statement, TLX key metrics, TLX chart. See the TLX stock overview for the latest quote and news.
TLX forecast FAQ
What is Telix Pharmaceuticals's price target?
The average analyst price target for Telix Pharmaceuticals is $20.57, 92.4% above the latest close of $10.69.
Is Telix Pharmaceuticals a buy, hold or sell?
Of 5 analysts covering Telix Pharmaceuticals, 5 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Telix Pharmaceuticals's EPS forecast?
Analysts forecast $0.15 per share for 2026 (range $0.03 to $0.39); for 2027 the estimate is −$0.04.
What is Telix Pharmaceuticals's revenue forecast?
The average revenue estimate for 2026 is $1.4 billion, growth of 16.1%; for 2027 it is $1.6 billion.
Does Telix Pharmaceuticals usually beat earnings estimates?
Telix Pharmaceuticals reported EPS at or above the analyst estimate in 4 of the last 6 quarters.